Award recordCONTRACT

KREMERS URBAN PHARMACEUTICALS INC.

PIID VA797P16J0056· VA Staff Offices· NAC PHARMACEUTICALS 36P797· 6505 · DRUGS AND BIOLOGICALS· FY2016· $1,745,344 net obligations· UEI UW6UVG3T5LX6· IN

Description

OMEPRAZOLE CAPSULES

First action · last action
2016-04-14 · 2016-06-24
Transactions
3
First transaction's obligation
$1,897,533
Base + all options value (sum of deltas)
$1,745,344
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
VA797P13A0006
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 3 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$1,897,533$0Base award · 2016-04-14 · this action $1,897,533 · running total $1,897,533Modification P00001 · 2016-06-07 · this action -$151,536 · running total $1,745,997Modification P00002 · 2016-06-24 · this action -$653 · running total $1,745,344
  • Base2016-04-14+$1,897,533= $1,897,533
  • Mod P000012016-06-07-$151,536= $1,745,997
  • Mod P000022016-06-24-$653= $1,745,344
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2016-04-14+$1,897,533$1,897,533OMEPRAZOLE CAPSULES
Mod P00001· FUNDING ONLY ACTION2016-06-07−$151,536$1,745,997OMEPRAZOLE CAPSULES
Mod P00002· FUNDING ONLY ACTION2016-06-24−$653$1,745,344OMEPRAZOLE CAPSULES

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI UW6UVG3T5LX6)

AwardOffice · PSC / listingNet obligationsFY
36E79720N0017NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$583,106FY2020
36E79720N0014NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$845,319FY2020
36E79720N0011NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$669,466FY2020
36E79720N0007NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$374,423FY2020
36E79720N0006NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$277,856FY2020
36E79720N0002NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$393,081FY2020

Other recipients under 6505 from NAC PHARMACEUTICALS 36P797 (most recent first)

AwardRecipientOfficeNet obligationsFY
VA797P17J0053EXELAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$88,200FY2017
VA797P17J0052MYLAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$6,169FY2017
VA797P17J0051MYLAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$17,881FY2017
VA797P17J0050MYLAN PHARMACEUTICALS INCNAC PHARMACEUTICALS 36P797$72,904FY2017
VA797P17J0054EXCELLIUM PHARMACEUTICAL INC.NAC PHARMACEUTICALS 36P797$48,519FY2017

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA797P16J0056_3600_VA797P13A0006_3600 · retrieved 2026-09-26.